E. Davis - 25 Nov 2025 Form 4 Insider Report for QUEST DIAGNOSTICS INC (DGX)

Role
CEO and President, Director
Signature
Sean D. Mersten, Attorney in Fact for James E. Davis
Issuer symbol
DGX
Transactions as of
25 Nov 2025
Transactions value $
-$10,589,760
Form type
4
Filing time
28 Nov 2025, 16:30:50 UTC
Previous filing
07 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Davis J. E. CEO and President, Director 500 PLAZA DRIVE, SECAUCUS Sean D. Mersten, Attorney in Fact for James E. Davis 28 Nov 2025 0001599837

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DGX Common Stock Options Exercise $5.28M +55.1K +45.73% $95.80 176K 25 Nov 2025 Direct F1
transaction DGX Common Stock Sale -$1.79M -9.34K -5.32% $191.59 166K 25 Nov 2025 Direct F1, F2
transaction DGX Common Stock Sale -$7.88M -41K -24.67% $192.27 125K 25 Nov 2025 Direct F1, F3
transaction DGX Common Stock Sale -$916K -4.75K -3.79% $192.97 120K 25 Nov 2025 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DGX Non-Qualifed Stock Option (right to buy) Options Exercise -$5.28M -55.1K -100% $95.80 0 25 Nov 2025 Common Stock 55.1K $95.80 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
F2 This transaction was executed in multiple trades at prices ranging from $190.810 to $191.805. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 This transaction was executed in multiple trades at prices ranging from $191.820 to $192.810. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 This transaction was executed in multiple trades at prices ranging from $192.820 to $193.310. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5 The options vested in three equal annual installments beginning on the first annual anniversary of the grant date.